DIAgnostics for Multidrug Resistant Tuberculosis in Africa (DIAMA)
The DIAMA study aimed to address current gaps in diagnosing and managing patients with Multi-Drug-Resistant (MDR) tuberculosis. It aimed to evaluate and implement rapid and accurate molecular tests for several anti-tuberculosis drugs. Beginning in 2017, a cohort of over 3,000 participants aged 15 years and older from countries in West, Central, and East Africa with tuberculosis was recruited. Participants underwent various diagnostic tests at baseline, and those who were resistant to the treatment Rifampicin were followed up longitudinally.
Study design
Cohort, Cohort - clinical
Number of participants at first data collection
3,356 (participants)
Age at first data collection
≥ 15 years (participants)
Participant year of birth
Varied (participants)
Participant sex
All
Representative sample at baseline?
No
Sample features
Countries
Year of first data collection
2017
Primary Institutions
National Reference Laboratory of Mycobacteria (Laboratoire de Référence des Mycobactéries)
Links
clinicaltrials.gov/show/NCT03303963
publications.edctp.org/international-partnerships-against-infectious-diseases/diama
research.itg.be/en/projects/culture-free-diagnosis-and-follow-up-of-multidrug-resistant-tuber
Profile paper DOI
Not available
Funders
European Union (EU)
European and Developing Clinical Trial Partnership (EDCTP)
Ongoing?
No
Data types collected
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- None
- None
- None
Engagement
Keywords
